Inducible nitric oxide synthase expression in melanoma: Implications in lymphangiogenesis

Modern Pathology

Volumn 22, Issue 1, 2009, Pages 21-30

  Massi, Daniela ^a   De Nisi, Maria C ^b   Franchi, Alessandro ^a   Mourmouras, Vasileios ^b   Baroni, Gianna ^a   Panelos, John ^a   Santucci, Marco ^a   Miracco, Clelia ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

CD105; D2 40; iNOS; Melanoma; Microvessel density; Nevi

Indexed keywords

ENDOGLIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY D2-40;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; MELANOCYTIC NEVUS; MELANOMA; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEVUS, PIGMENTED; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS;

EID: 58149172074     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.128     Document Type: Article

References (44)

1. Kleinert H, Pautz A, Linker K, et al. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-266.
2. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392-4396.
3. Cobbs CS, Brenman JE, Aldape KD, et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-730.
4. Thomsen LL, Miles DW, Happerfield L, et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44.
5. Franchi A, Massi D, Santucci M, et al. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol 2006;208:439-445.
6. Joshi M, Strandhoy J, White WL. Nitric oxide synthase activity is up-regulated in melanoma cell lines: a potential mechanism for metastases formation. Melanoma Res 1996;6:121-126.
7. Fukumura D, Jain RK. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 1998;17:77-89.
8. Ohhashi T, Mizuno R, Ikomi F, et al. Current topics of physiology and pharmacology in the lymphatic system. Pharmacol Ther 2005;105:165-188.
9. Salvucci O, Carsana M, Bersani I, et al. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001;61:318-326.
10. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004;279:288-298.
11. Zheng M, Ekmekcioglu S, Walch ET, et al. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004;14:165-171.
12. Tschugguel W, Pustelnik T, Lass H, et al. Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 1999;79:1609-1612.
13. Ekmekcioglu S, Ellerhorst J, Smid CM, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6:4768-4775.
14. Massi D, Franchi A, Sardi I, et al. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001;194: 194-200.
15. Ekmekcioglu S, Ellerhorst JA, Mumm JB, et al. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther 2003;2:9-17.
16. Ekmekcioglu S, Ellerhorst JA, Prieto VG, et al. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861-866.
17. Ahmed B, Van Den Oord JJ. Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin. Br J Dermatol 2000;142:432-440.
18. Ambs S, Merriam WG, Bennett WP, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998;58:334-341.
19. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-596.
20. Reveneau S, Arnould L, Jolimoy G, et al. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 1999;79:1215-1225.
21. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
22. Lin Z, Chen S, Ye C, et al. Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res 2003;31:232-235.
23. Maeda H, Noguchi Y, Sato K, et al. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994;85:331-334.
24. Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997;57:948-955.
25. Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J 2000;14:1889-1900.
26. Nam HY, Choi BH, Lee JY, et al. The role of nitric oxide in the particulate matter (PM2.5)-induced NFkappaB activation in lung epithelial cells. Toxicol Lett 2004;148:95-102.
27. Massi D, Marconi C, Franchi A, et al. Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors. Hum Pathol 2007;38:1516-1525.
28. Mizuno R, Koller A, Kaley G. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. Am J Physiol 1998;274:R790-R796.
29. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006;12:1201-1207.
30. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893-903.
31. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005;18:1232-1242.
32. Fonsatti E, Altomonte M, Nicotra MR, et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003;22:6557-6563.
33. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-235.
34. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22:3172-3179.
35. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-1886.
36. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-1960.
37. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:250-256.
38. Giorgadze TA, Zhang PJ, Pasha T, et al. Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol 2004;31:672-677.
39. Shields JD, Borsetti M, Rigby H, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004;90:693-700.
40. Valencak J, Heere-Ress E, Kopp T, et al. Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma. Eur J Cancer 2004;40:358-364.
41. Sahni D, Robson A, Orchard G, et al. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol 2005;58:715-721.
42. Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006;59:166-173.
43. Saharinen P, Tammela T, Karkkainen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004;25:387-395.
44. Shields JD, Emmett MS, Dunn DB, et al. Chemokine-mediated migration of melanoma cells towards lymphatics - a mechanism contributing to metastasis. Oncogene 2007;26:2997-3005.